Annovis Bio, Inc. (ANVS)
NYQ · Healthcare · Biotechnology
$1.78
-2.73%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$75.7M
Shares Outstanding
42.5M
Exchange
NYQ
Currency
USD
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -6.3M | -7.4M | -9.7M | -18.0M |
| Net Income | -6.2M | -7.3M | -9.8M | -17.6M |
| Diluted EPS | $-0.32 | $-0.37 | $nan | $-0.63 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -25.5M | -45.0M | -26.7M | -29.7M |
| Net Income | -25.3M | -56.2M | -24.6M | -28.9M |
| Diluted EPS | $-3.10 | $-6.23 | $-2.31 | $-1.40 |